PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.

Abstract Resistance to platinum-based chemotherapy remains a great challenge for ovarian cancer treatment. The human let-7 family contains 13 members located on nine different chromosomes, and most members have been implicated in the modulation of drug sensitivity in cancers. Our previous study showed that deregulation of let-7e in epithelial ovarian cancer (EOC) promoted the development of resistance to cisplatin. In the present study, we aimed to investigate the underlying mechanism and further evaluate the clinical value of let-7e in predicting chemo-response and prognosis in EOC.
PMID
Related Publications

Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin.

BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.

Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

Authors

Mayor MeshTerms

DNA Breaks, Double-Stranded

DNA Repair

Keywords

BRCA1

Cisplatin

DSB

Let-7e

Ovarian cancer

Rad51

Journal Title journal of ovarian research
Publication Year Start




PMID- 28376831
OWN - NLM
STAT- MEDLINE
DA  - 20170405
DCOM- 20170418
LR  - 20170418
IS  - 1757-2215 (Electronic)
IS  - 1757-2215 (Linking)
VI  - 10
IP  - 1
DP  - 2017 Apr 04
TI  - Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA
      double strand break repair.
PG  - 24
LID - 10.1186/s13048-017-0321-8 [doi]
AB  - BACKGROUND: Resistance to platinum-based chemotherapy remains a great challenge
      for ovarian cancer treatment. The human let-7 family contains 13 members located 
      on nine different chromosomes, and most members have been implicated in the
      modulation of drug sensitivity in cancers. Our previous study showed that
      deregulation of let-7e in epithelial ovarian cancer (EOC) promoted the
      development of resistance to cisplatin. In the present study, we aimed to
      investigate the underlying mechanism and further evaluate the clinical value of
      let-7e in predicting chemo-response and prognosis in EOC. RESULTS: In situ
      hybridization assays revealed a significantly decreased expression of let-7e in
      chemo-resistant EOC tissues compared with chemo-sensitive cases. Transfection
      with let-7e agomir sensitized EOC cells to cisplatin, down-regulated BRCA1 and
      Rad51 expression, and repressed the repair of cisplatin-induced DNA double strand
      break, while let-7e inhibitor exerted the opposite effects. In human EOC tissues,
      BRCA1 and Rad51 levels were increased in the chemo-resistant group compared with 
      the sensitive group and were negatively correlated with let-7e. Low let-7e and
      high Rad51 were significantly associated with poor progression-free survival and 
      overall survival and multivariate regression analyses showed that let-7e was an
      independent predictor for overall survival and chemotherapy response in EOC.
      Receiver operating characteristic analysis indicated that let-7e level was highly
      predictive of resistance to platinum-taxane chemotherapy with an area under the
      curve of 0.826. CONCLUSIONS: In EOC, low let-7e leads to activation of BRCA1 and 
      Rad51 expression and subsequent enhancement of DSB repair, which in turn results 
      in cisplatin-resistance. Let-7e is a potential predictor for survival and
      chemo-response in EOC and re-expression of let-7e might be an effective strategy 
      for overcoming chemo-resistance.
FAU - Xiao, Man
AU  - Xiao M
AD  - Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan,
      430022, China.
FAU - Cai, Jing
AU  - Cai J
AD  - Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan,
      430022, China.
FAU - Cai, Liqiong
AU  - Cai L
AD  - Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan,
      430022, China.
FAU - Jia, Jinghui
AU  - Jia J
AD  - Department of Obstetrics and Gynecology, Air Force General Hospital, PLA,
      Beijing, 100142, China.
FAU - Xie, Lisha
AU  - Xie L
AD  - Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan,
      430022, China.
FAU - Zhu, Ying
AU  - Zhu Y
AD  - Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan,
      430022, China.
FAU - Huang, Bangxing
AU  - Huang B
AD  - Department of Pathology, Union Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022,
      China.
FAU - Jin, Dongdong
AU  - Jin D
AD  - Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan,
      430022, China.
FAU - Wang, Zehua
AU  - Wang Z
AD  - Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan,
      430022, China. [email protected]
LA  - eng
PT  - Journal Article
DEP - 20170404
PL  - England
TA  - J Ovarian Res
JT  - Journal of ovarian research
JID - 101474849
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
RN  - 0 (MicroRNAs)
RN  - 0 (mirnlet7 microRNA, human)
RN  - EC 2.7.7.- (RAD51 protein, human)
RN  - EC 2.7.7.- (Rad51 Recombinase)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Ovarian epithelial cancer
SB  - IM
MH  - Adult
MH  - Aged
MH  - BRCA1 Protein/genetics/metabolism
MH  - Cell Line, Tumor
MH  - Cisplatin/pharmacology
MH  - *DNA Breaks, Double-Stranded
MH  - *DNA Repair
MH  - Drug Resistance, Neoplasm/genetics
MH  - Female
MH  - Humans
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasms, Glandular and Epithelial/drug therapy/*genetics/*metabolism
MH  - Ovarian Neoplasms/drug therapy/*genetics/*metabolism
MH  - Prognosis
MH  - Rad51 Recombinase/genetics/metabolism
PMC - PMC5379542
OTO - NOTNLM
OT  - BRCA1
OT  - Cisplatin
OT  - DSB
OT  - Let-7e
OT  - Ovarian cancer
OT  - Rad51
EDAT- 2017/04/06 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/06 06:00
PHST- 2016/08/23 [received]
PHST- 2017/03/28 [accepted]
AID - 10.1186/s13048-017-0321-8 [doi]
AID - 10.1186/s13048-017-0321-8 [pii]
PST - epublish
SO  - J Ovarian Res. 2017 Apr 4;10(1):24. doi: 10.1186/s13048-017-0321-8.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>